Alnylam to seek approval for second RNAi drug

Alnylam thinks it has strong enough clinical data for its gene-silencing drug for rare disease acute hepatic porphyria (AHP), and plans to move ahead with regulatory filings in the US and Europe. The US biotech made a bit of biotech history last August after getting the first-ever FDA approval for a gene-silencing drug based on RNA interference (RNAi) technology – Onpattro (patisiran) for hereditary transthyretin-mediated amyloidosis (hATTR).
Read more...

;